Clinical use of iron chelators

Iron Physiology and Pathophysiology in Humans

Volumn , Issue , 2012, Pages 591-627

  Porter, John B ^a   Hershko, Chaim ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Chelation therapy; Chelator; Deferasirox; Deferiprone; Deferoxamine; Heart; Iron overload; Liver; Non transferrin bound iron; Toxicity

Indexed keywords

EID: 84983211453     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-485-2_28     Document Type: Chapter

References (183)

1. Andrews NC. A genetic view of iron homeostasis. Semin Hematol. 2002;39:227-34.
2. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783-8.
3. Finch CA, Deubelbeiss K, Cook JD, et al. Ferrokinetics in man. J Clin Invest. 1970;49:17-53.
4. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096-101.
5. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in thalassemia major. Blood. 2008;111:583-7.
6. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168-76.
7. Fung EB, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol. 2007;82:255-65.
8. Hershko C, Graham G, Bates G, Rachmilewitz E. Non-specific serum iron in thalassaemia; an abnormal serum fraction of potential toxicity. Br J Haematol. 1978;40:255-63.
9. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem. 1989;264:4417-22.
10. Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem. 2008;13:57-74.
11. Gutteridge J, Rowley D, Griffiths E, Halliwell B. Low molecular weight iron complexes and oxygen radical reactions in idiopathic hemochromatosis. Clin Sci. 1985;68:463-7.
12. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277-87.
13. Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9:1187-94.
14. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2:27-30.
15. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-31.
16. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187-93.
17. Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304:319-24.
18. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51:209-21.
19. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632-9.
20. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 2005;352:536-8.
21. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588-90.
22. Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol. 2001;38:57-62.
23. Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81:858-63.
24. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol. 2005;80:70-4.
25. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol. 2006;135:574-82.
26. Westwood MA, Shah F, Anderson LJ, et al. Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. J Magn Reson Imaging. 2007;26:564-8.
27. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-6.
28. Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol. 2007;82:1136-9.
29. Cartwright GE, Edwards CQ, Kravitz K, et al. Hereditary hemochromatosis. Phenotypic expression of the disease. N Engl J Med. 1979;301:175-9.
30. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327-31.
31. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9.
32. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2 cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-55.
33. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major [see comments]. N Engl J Med. 1994;331:567-73.
34. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971-7.
35. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17-21.
36. Angelucci E, Giovagnoni A, Valeri G, et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood. 1997;90:4736-42.
37. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med. 1982;307:1671-5.
38. Piga A, Fischer R, St Pierre T, et al. Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with beta-thalassemia, treated with deferasirox (Exjade ®, ICL670). Blood 2005;106:Abstract 2689.
39. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855-61.
40. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357-62.
41. Garbowski M, Carpenter JP, Smith G, Pennell D, Porter JB. Calibration of improved T2 method for the estimation of liver iron concentration in transfusional iron overload. Blood 2009;114:Abstract 2004.
42. Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavalin a: patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol. 1980;46:409-16.
43. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42:81-5.
44. Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. Acta Haematol. 1987;78:198-205.
45. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92:583-8.
46. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121:938-48.
47. Ang A, Shah F, Davis B, et al. Deferiprone is associated with Lower Serum Ferritin (SF) relative to Liver Iron Concentration (LIC) than Deferoxamine and Deferasirox-implications for clinical practice. Blood 2010;116:Abstract 4246.
48. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous betathalassemia. N Engl J Med. 1994;331:574-8.
49. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
50. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263-9.
51. Carpenter JP, He T, Kirk P, et al. On t2 magnetic resonance and cardiac iron. Circulation. 2011;123:1519-28.
52. Kirk P, Roughton M, Porter JB, et al. Cardiac T2 magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-8.
53. Thomas A, Garbowski M, Ang A, et al. A decade follow-up of a Thalassemia Major (TM) cohort monitored by Cardiac Magnetic Resonance Imaging (CMR): Significant reduction in patients with cardiac iron and in total mortality. Blood 2010;116:Abstract 1011.
54. Kirk P, He T, Anderson LJ, et al. International reproducibility of single breathhold T2 MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32:315-9.
55. Sephton-Smith R. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J. 1962;2:1577-80.
56. Pippard M, Johnson D, Callender S, Finch C. Ferrioxamine excretion in iron loaded man. Blood. 1982;60:288-94.
57. Jacobs EM, Hendriks JC, van Tits BL, et al. Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Anal Biochem. 2005;341:241-50.
58. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood. 2004;104:1504-10.
59. Daar S, Taher A, Pathare A, et al. Plasma LPI in thalassemia patients before and after treatment with deferasirox (Exjade ®, ICL670). Blood 2005;106:Abstract 2697.
60. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of nontransferrin- bound plasma iron with deferoxamine therapy. Blood. 1996;88:705-13.
61. Shah F, Westwood MA, Evans PJ, Porter JB. Discordance in MRI assessment of iron distribution and plasma NTBI between transfusionally iron loaded adults with sickle cell and thalassaemia syndromes. Blood. 2002;100:468a.
62. Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254-63.
63. Porter J, Cappellini M, El-Beshlawy A, et al. Effect of deferasirox (Exjade ®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood 2008;112:Abstract 3881.
64. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148:466-75.
65. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91-6.
66. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15:329-68.
67. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112:2973-8.
68. Rothman RJ, Serroni A, Farber JL. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Mol Pharmacol. 1992;42:703-10.
69. Klausner R, Rouault T, Harford J. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell. 1993;72:19-28.
70. Breuer W, Epsztejn S, Cabantchik Z. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett. 1997;382:304-8.
71. Hershko C, Weatherall D. Iron chelating therapy. CRC Crit Rev Clin Lab Sci. 1988;26:303-45.
72. Porter J, Gyparaki M, Burke L, et al. Iron mobilization from hepatocyte monolayer cultures by Chelators: the importance of membrane permeability and the iron binding constant. Blood. 1988;72:1497-503.
73. Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, Hider RC. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood. 1990;76:2389-96.
74. Porter JB, Singh S, Hoyes KP, Epemolu O, Abeysinghe RD, Hider RC. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds. Adv Exp Med Biol. 1994;356:361-70.
75. Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol. 1993;85:393-400.
76. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106:3242-50.
77. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem. 1996;271:20291-9.
78. Porter JB, Rafique R, Srichairatanakool S, et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann N Y Acad Sci. 2005;1054:155-68.
79. Lee P, Mohammed N, Abeysinghe RD, Hider RC, Porter JB, Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients. Drug Metab Dispos. 1993;21:640-4.
80. Porter JB, Faherty A, Stallibrass L, Brookman L, Hassan I, Howes C. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Ann N Y Acad Sci. 1998;850:483-7.
81. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood. 2001;97:792-8.
82. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the shuttling of plasma non-transferrinbound iron (NTBI) onto deferoxamine by deferiprone. Transl Res. 2010;156:55-67.
83. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455-62.
84. Modell B, Letsky E, Flynn D, Peto R, Weatherall D. Survival and desferrioxamine in thalassaemia major. Br Med J. 1982;284:1081-4.
85. Gabutti V, Borgna-Pignatti C. Clinical manifestations and therapy of transfusional haemosiderosis. Baillieres Clin Haematol. 1994;7:919-40.
86. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229-36.
87. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. Eur J Haematol. 2003;70:398-403.
88. Marcus RE, Davies SC, Bantock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron overloaded patients with thalassaemia major. Lancet. 1984;1:392-3.
89. Davies SC, Marcus RE, Hungerford JL, Miller HM, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2:181-4.
90. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73:403-9.
91. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in north America. Blood. 2004;104:34-9.
92. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-44.
93. Barry M, Flynn D, Letsky E, Risdon R. Long term chelation therapy in thalassaemia: effect on liver iron concentration, liver histology and clinical progress. Br Med J. 1974;2:16-20.
94. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med. 1990;323:713-9.
95. Fosburg M, Nathan DG. Treatment of Cooley's anaemia. Blood. 1990;76:435-44.
96. Porter JB, Huehns ER. The toxic effects of desferrioxamine. Baillieres Clin Haematol. 1989;2:459-74.
97. Bentur Y, Koren G, Tesoro A, Carley H, Olivieri N, Freedman MH. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clin Pharmacol Ther. 1990;47:478-82.
98. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314:869-73.
99. Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med. 1985;56:345-55.
100. De Virgillis S, Congia M, Frau F, et al. Desferrioxamine-induced growth retardation in patients with thalassaemia major. J Pediatr. 1988;113:661-9.
101. Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High dose desferrioxamine as a cause of growth failure in thalassaemic patients. Eur J Haematol. 1988;40:380-1.
102. Olivieri NF, Koren G, Harris J, et al. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol. 1992;14:48-56.
103. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK thalassaemia register. Lancet. 2000;355:2051-2.
104. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta. 1979;586:278-97.
105. Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin Hematol. 1990;27:112-6.
106. Richardson DR, Ponka P. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs. J Lab Clin Med. 1998;132:351-2.
107. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10:1065-76.
108. Bergeron R, Wiegand J, McManis Jea. Structure-activity relationships among desazadesferrithiocin analogues. In hershko C. Iron chelation therapy. Adv Exp Med Biol. 2002;509:167-84.
109. Donovan JM, Plone M, Dagher R, Bree M, Marquis J. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci. 2005;1054:492-4.
110. Barton JC. Drug evaluation: deferitrin for iron overload disorders. IDrugs. 2007;10:480-90.
111. Anderegg G, Raeber M. Metal complex formation of a new siderophore desferrithiocin and of three related ligands. J Chem Soc, Chem Commun. 1990;17:1194-6.
112. Rienhoff Jr HY, Viprakasit V, Tay L, et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica. 2011;96:521-5.
113. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J (Clin Res Ed). 1987;295:1509-12.
114. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583-7.
115. Hider RC, Choudhury R, Rai BL, Dehkordi LS, Singh S. Design of orally active iron chelators. Acta Haematol. 1996;95:6-12.
116. Liu ZD, Kayyali R, Hider RC, Porter JB, Theobald AE. Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators. J Med Chem. 2002;45:631-9.
117. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in ironloaded patients. Lancet. 1990;336:1275-9.
118. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol. 1990;48:255-61.
119. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs. 1999;58:553-78.
120. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17-24.
121. Porter JB, Abeysinghe RD, Hoyes KP, et al. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3- hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site. Br J Haematol. 1993;85:159-68.
122. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture. Blood. 1991;77:2049-53.
123. Kayyali R, Porter JB, Liu ZD, et al. Structure-function investigation of the interaction of 1- and 2-substituted 3-hydroxypyridin-4-ones with 5-lipoxygenase and ribonucleotide reductase. J Biol Chem. 2001;15:15.
124. Al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403-8.
125. Glickstein H, El RB, Link G, et al. Action of Chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108:3195-203.
126. Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl- 3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood. 1994;83:2329-33.
127. Roberts D, Brunskill S, Doree C, Williams S, Howard J, Hyde C. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2007;18(3):CD004839.
128. Olivieri N, Brittenham G. Final results of the randomised trial of deferiprone and deferoxamine. Blood. 1997;90:264a.
129. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196-208.
130. Ha SY, Chik KW, Ling SC, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin. 2006;30:263-74.
131. Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007;92:1599-606.
132. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey R, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one (L1) in thalassemia major. Blood. 1992;80:593-9.
133. Agarwal MB, Gupte SS, Viswanathan C, et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992;82:460-6.
134. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major [see comments]. N Engl J Med. 1995;332:918-22.
135. Hoffbrand AV FA-R, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood. 1998;91:295-300.
136. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108:305-12.
137. Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr. 2004;41:21-7.
138. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330-6.
139. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-96.
140. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733-7.
141. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in betathalassaemia. Lancet. 2002;360:516-20.
142. Ceci A, Felisi M, De Sanctis V, De Mattia D. Pharmacotherapy of iron overload in thalassaemic patients. Expert Opin Pharmacother. 2003;4:1763-74.
143. Al-Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol. 1994;53:298-301.
144. Cunningham JM, Al-Refaie FN, Hunter AE, Sheppard LN, Hoffbrand AV. Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. Eur J Haematol. 1994;52:176-9.
145. Hoyes KP, Jones HM, Abeysinghe RD, Hider RC, Porter JB. In vivo and in vitro effects of 3-hydroxypyridin- 4-one chelators on murine hemopoiesis. Exp Hematol. 1993;21:86-92.
146. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dimethyl-3- hydroxypyrid-4-one (L1). II. clinical observations. Br J Haematol. 1990;76:301-4.
147. Cermak J, Brabec V. Treatment of iron overload states with oral administration of the chelator agent, L1 (deferiprone). Vnitr Lek. 1994;40:586-90.
148. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol. 2005;74:217-20.
149. Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol. 1998;101:413-5.
150. Berdoukas V, Bohane T, Eagle C, et al. The Sydney Children's hospital experience with the oral iron chelator deferiprone (L1). Transfus Sci. 2000;23:239-40.
151. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 2002;100:1566-9.
152. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the international study group on oral iron Chelators. Br J Haematol. 1995;91:224-9.
153. Choudhry VP, Pati HP, Saxena A, Malaviya AN. Deferiprone, efficacy and safety. Indian J Pediatr. 2004;71:213-6.
154. Alert SOS; 2006.
155. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-8.
156. Hershko C, Link G, Konijn A, Cabantchik Z. Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci. 2005;1054:124-35.
157. Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006;91:1241-3.
158. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187-9.
159. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876-84.
160. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90:1309-14.
161. Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis. 2006;36:21-5.
162. Telfer P, Coen P. Christou Sea. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica. 2006;91:1187-92.
163. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97:1115-22.
164. Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535-43.
165. Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010;38:808-16.
166. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43:565-72.
167. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361: 1597-602.
168. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-80.
169. Cappellini M, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118(4):884-93.
170. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95:557-66.
171. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501-8.
172. Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (exjade ®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154(3):387-97.
173. Lee JW, Yoon SS, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010;116(14):2448-54.
174. Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34:1143-50.
175. Porter J, Lin K, Beris P, et al. Response of iron overload in rare transfusion-dependent anaemias to deferasirox: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol. 2011;87(4):338-48.
176. Porter JB, Tanner MA, Pennell DJ. Improved myocardial T2 in transfusion dependent anemias receiving ICL670 (Deferasirox). Blood 2005;106:Abstract 3600.
177. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010;115:2364-71.
178. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2 over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96:48-54.
179. Pennell D, Porter J, Cappellini M, et al. Continued improvement and normalization of myocardial T2 in patients with ß thalassemia major treated with deferasirox (Exjade ®) for up to 3 years. Blood 2010;116:Abstract #28641.
180. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of 30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752-9.
181. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82:458-65.
182. Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114:4009-13.
183. Lal A, Sweeters N, Ng V, et al. Combined chelation therapy with deferasirox and deferoxamine in transfusiondependent thalassemia. Blood 2010;116:Abstract 4269.